Wang YZ - Search Results

1

Characterization of structural, biochemical, pharmacokinetic, and pharmacodynamic properties of the LSD1 inhibitor bomedemstat in preclinical models.

Jasmine S, Mandl A, Krueger TEG, Dalrymple SL, Antony L, Dias J, Celatka CA, Tapper AE, Kleppe M, Kanayama M, Jing Y, Speranzini V, Wang YZ, Luo J, Trock BJ, Denmeade SR, Carducci MA, Mattevi A, Rienhoff HY Jr, Isaacs JT, Nathaniel Brennen W. Jasmine S, et al. Among authors: wang yz. Prostate. 2024 Apr 15. doi: 10.1002/pros.24707. Online ahead of print. Prostate. 2024. PMID: 38619005

2

Paracrine regulation of apoptosis by steroid hormones in the male and female reproductive system.

Kurita T, Wang YZ, Donjacour AA, Zhao C, Lydon JP, O'Malley BW, Isaacs JT, Dahiya R, Cunha GR. Kurita T, et al. Among authors: wang yz. Cell Death Differ. 2001 Feb;8(2):192-200. doi: 10.1038/sj.cdd.4400797. Cell Death Differ. 2001. PMID: 11313721

3

Quantitation of apoptotic activity following castration in human prostatic tissue in vivo.

Staack A, Kassis AP, Olshen A, Wang Y, Wu D, Carroll PR, Grossfeld GD, Cunha GR, Hayward SW. Staack A, et al. Prostate. 2003 Feb 15;54(3):212-9. doi: 10.1002/pros.10179. Prostate. 2003. PMID: 12518326

4

Development and characterization of efficient xenograft models for benign and malignant human prostate tissue.

Wang Y, Revelo MP, Sudilovsky D, Cao M, Chen WG, Goetz L, Xue H, Sadar M, Shappell SB, Cunha GR, Hayward SW. Wang Y, et al. Prostate. 2005 Jul 1;64(2):149-59. doi: 10.1002/pros.20225. Prostate. 2005. PMID: 15678503

5

Sulfasalazine-induced cystine starvation: potential use for prostate cancer therapy.

Doxsee DW, Gout PW, Kurita T, Lo M, Buckley AR, Wang Y, Xue H, Karp CM, Cutz JC, Cunha GR, Wang YZ. Doxsee DW, et al. Among authors: wang y, wang yz. Prostate. 2007 Feb 1;67(2):162-71. doi: 10.1002/pros.20508. Prostate. 2007. PMID: 17075799

6

Use of irinotecan for treatment of small cell carcinoma of the prostate.

Tung WL, Wang Y, Gout PW, Liu DM, Gleave M, Wang Y. Tung WL, et al. Prostate. 2011 May 15;71(7):675-81. doi: 10.1002/pros.21283. Epub 2010 Oct 14. Prostate. 2011. PMID: 20949523

7

Genistein versus ICI 182, 780: an ally or enemy in metastatic progression of prostate cancer.

Nakamura H, Wang Y, Xue H, Romanish MT, Mager DL, Helgason CD, Wang Y. Nakamura H, et al. Prostate. 2013 Dec;73(16):1747-60. doi: 10.1002/pros.22712. Epub 2013 Aug 26. Prostate. 2013. PMID: 24038102

8

Movember GAP1 PDX project: An international collection of serially transplantable prostate cancer patient-derived xenograft (PDX) models.

Navone NM, van Weerden WM, Vessella RL, Williams ED, Wang Y, Isaacs JT, Nguyen HM, Culig Z, van der Pluijm G, Rentsch CA, Marques RB, de Ridder CMA, Bubendorf L, Thalmann GN, Brennen WN, Santer FR, Moser PL, Shepherd P, Efstathiou E, Xue H, Lin D, Buijs J, Bosse T, Collins A, Maitland N, Buzza M, Kouspou M, Achtman A, Taylor RA, Risbridger G, Corey E. Navone NM, et al. Prostate. 2018 Dec;78(16):1262-1282. doi: 10.1002/pros.23701. Epub 2018 Aug 2. Prostate. 2018. PMID: 30073676

9

SRRM4 gene expression correlates with neuroendocrine prostate cancer.

Li Y, Zhang Q, Lovnicki J, Chen R, Fazli L, Wang Y, Gleave M, Huang J, Dong X. Li Y, et al. Prostate. 2019 Jan;79(1):96-104. doi: 10.1002/pros.23715. Epub 2018 Aug 28. Prostate. 2019. PMID: 30155992

10

T-type calcium channels drive the proliferation of androgen-receptor negative prostate cancer cells.

Silvestri R, Pucci P, Venalainen E, Matheou C, Mather R, Chandler S, Aceto R, Rigas SH, Wang Y, Rietdorf K, Bootman MD, Crea F. Silvestri R, et al. Prostate. 2019 Sep;79(13):1580-1586. doi: 10.1002/pros.23879. Epub 2019 Jul 23. Prostate. 2019. PMID: 31334879

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

1,935 results

Search Page